Cutaneous manifestations in neuro-oncology: clinically relevant tumor and treatment associated dermatologic findings
Skin findings are a rare but important aspect of the evaluation and management of patients with tumors of the nervous system. Skin findings have the highest prevalence in genetic tumor syndromes termed neuro-genodermatoses, which include neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and tuberous sclerosis. Skin changes are observed in patients with non-syndromic nervous system malignancy, often as a result of pharmacotherapy. The skin may also manifest findings in paraneoplastic conditions that affect the nervous system, providing an early indication of underlying neoplasm, including dermatomyosistis, neu...
Source: Seminars in Oncology - February 21, 2016 Category: Cancer & Oncology Authors: Roy E. Strowd, Lindsay C. Strowd, Jaishri O. Blakeley Source Type: research
Cutaneous manifestations of breast cancer
Breast cancer may present with cutaneous symptoms. The skin manifestations of breast cancer are varied. Some of the more common clinical presentations of metastatic cutaneous lesions from breast cancer will be described. Paraneoplastic cutaneous dermatoses have been reported as markers of breast malignancy and include erythema gyratum repens, acquired ichthyosis, dermatomyositis, multicentric reticulohistiocytosis, and hypertrichosis lanuginosa acquisita. Mammary Paget ’s disease, often associated with an underlying breast cancer, and Cowden syndrome, which has an increased risk of breast malignancy, each have specific d...
Source: Seminars in Oncology - February 21, 2016 Category: Cancer & Oncology Authors: Antoinette R. Tan Source Type: research
Cutaneous manifestations associated with melanoma
Melanoma is a malignancy most commonly arising from the skin; therefore, primary melanoma characteristics are usually the first cutaneous manifestations of melanoma. Cutaneous metastases, which can occur locally or diffusely, are important to detect in a timely manner as treatments for advanced melanoma that impact survival are now available. Melanoma can be associated with local or diffuse pigmentation changes, including depigmentation associated with the leukodermas and hyperpigmentation associated with diffuse melanosis cutis. (Source: Seminars in Oncology)
Source: Seminars in Oncology - February 21, 2016 Category: Cancer & Oncology Authors: Ritva Vyas, Jacqueline Selph, Meg R. Gerstenblith Source Type: research
Partnering with skin to outsmart cancer: following leads provided by tumor-specific T cells
When Laura McGirt initiated this important and timely synthesis of the clinical and scientific linkage of systemic malignancies to dermatologic findings, I enthusiastically agreed to participate. My choice to pursue Dermatology was originally stimulated by Irwin Braverman ’s mentorship of me, when as an immunologically oriented Yale Medical School student, I fortuitously landed in the laboratory of the premier pioneer in medical dermatology. Irwin asked me to proofread the drafted chapters for the first edition of his seminal text on “Skin Signs of Systemic Disea ses” [1], for syntax, as he authored them. (Source: Seminars in Oncology)
Source: Seminars in Oncology - February 21, 2016 Category: Cancer & Oncology Authors: Richard L. Edelson Source Type: research
Cutaneous manifestations of nontargeted and targeted chemotherapies
This article reviews the cutaneous adverse reactions and treatment options of both conventional cytotoxic chemotherapeutic agents and newer targeted, multikinase inhibitors and immunomodulating therapies. (Source: Seminars in Oncology)
Source: Seminars in Oncology - February 21, 2016 Category: Cancer & Oncology Authors: Veronica J. Shi, Lauren L. Levy, Jennifer N. Choi Source Type: research
